Jeffrey Goldberg

About Jeffrey Goldberg

Jeffrey Goldberg’s NIH- and foundation-funded research is directed at neuroprotection and regeneration of retinal ganglion cells and the optic nerve, a major unmet need in glaucoma and other optic neuropathies. His laboratory is currently developing novel molecular, stem cell, and nanotherapeutics approaches for eye repair. He is broadly recognized for bringing together collaborative research programs in the lab and in the clinic, for example through the National Eye Institute’s Audacious Goals Initiative. This past year he has led the largest consortium funded under the ARPA-H total human eye allotransplantation (THEA) program, working towards whole eye transplantation for vision restoration. He has assembled 48 collaborating faculty across 24 institutions to work closely across scientific domains to bring this forward. Giving credit to his extended team, together they have already made remarkable strides in 2025 towards solving for trans-orbital surgical approaches, retinal survival, and optic nerve regeneration back to the brain in pre-clinical models.

In the clinic, Goldberg is widely known for designing and implementing FDA clinical trials for optic nerve neuroprotection and regeneration. His early-phase clinical trials in glaucoma and newest data showing evidence for anatomic and functional recovery in patients is credited for initiating a resurgence in interest in neuroprotection and vision restoration in glaucoma and other optic neuropathies. His discoveries and inventions have led to multiple startup companies bringing novel therapeutics and diagnostics through regulatory approval into commercialization, including the 2025 commercial clearance for a home visual field testing solution, and successful completion of a clinical trial for a cell therapy showing vision improvement in corneal disease. His goal is to translate scientific discoveries to patient therapies.